Jens Atzpodien - Concepedia

Author

Jens Atzpodien

Also Known As

, DGCIN – German Cooperative Renal Carcinoma Chemoimmunotherapy Trials Group, D. G. C. I. N. (German Cooperative Renal Carcinoma Chemo-Immunotherapy Trials Group), DGCIN – German Cooperative Renal Carcinoma Chemo-Immunotherapy Trials Group, J ATZPODIEN, J Atzpodien, J. ATZPODIEN, J. Atzpodien, JENS ATZPODIEN, Jens ATZPODIEN, Jens Atzpodien

210

Publications

6.5K

Citations

H-Index

Concepts

All Affiliations

Medizinische Hochschule Hannover Fachklinik Hornheide Memorial Sloan Kettering Cancer Center Ludwig-Maximilians-Universität München University of Münster

About

Jens Atzpodien is an author at Medizinische Hochschule Hannover specializing in medicine, oncology, and immunology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	25	47	3K
2	Health Sciences	7	7	463
3	Allergy	2	2	29
4	Engineering	1	1	37
5	Biostatistics	1	1	29

Jens Atzpodien

Publications

5.5K

Citations

H-Index

Page 1

	Year	Citations
Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by geneMAGE-3 and presented by HLA-A1 Marie Marchand, Nicolas van Baren, P. Weynants, International Journal of Cancer Subcutaneous InjectionsImmunologyImmunoeditingPathologyImmunotherapeutics	1999	786
Home therapy with recombinant interleukin-2 and interferon-$alpha;2b in advanced human malignancies Jens Atzpodien The Lancet Hematological MalignancyMedicineMalignant Blood DisorderImmunologyHome Therapy	1990	294
CXCR4/CXCL12 expression and signalling in kidney cancer Andres Jan Schrader, Oskar Lechner, Markus F. Templin, British Journal of Cancer	2002	254
Interleukin-2- and Interferon Alfa-2a-Based Immunochemotherapy in Advanced Renal Cell Carcinoma: A Prospectively Randomized Trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN) Jens Atzpodien, Hartmut Kirchner, Udo Jonas, Journal of Clinical Oncology	2004	224
Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC 2014-01 TPExtreme): a multicentre, open-label, randomised, phase 2 trial J. Guigay, Anne Aupérin, Jérôme Fayette, The Lancet Oncology Gortec 2014-01 TpextremeNeoadjuvant TherapyMedicineCisplatin Versus PlatinumHead And Neck Cancer	2021	214
Interleukin-2 Based Home Therapy of Metastatic Renal Cell Carcinoma: Risks and Benefits in 215 Consecutive Single Institution Patients Enrique Lopez Hänninen, Hartmut Kirchner, Jens Atzpodien The Journal of Urology	1996	194
FOLFOXIRI Plus Panitumumab As First-Line Treatment of <i>RAS</i> Wild-Type Metastatic Colorectal Cancer: The Randomized, Open-Label, Phase II VOLFI Study (AIO KRK0109) Dominik Paul Modest, Uwe M. Martens, Jorge Riera‐Knorrenschild, Journal of Clinical Oncology	2019	189
Prognostic factors for survival in patients with advanced renal cell carcinoma treated with recombinant interleukin-2 Peter Palmer, J. Vinke, Thierry Philip, Annals of Oncology Prognostic FactorsUrologyGenitourinary CancerMedicineImmune Checkpoint Inhibitor	1992	156
Peripheral Blood Tyrosinase Messenger RNA Detection and Survival in Malignant Melanoma Uta Kunter, Jan Buer, M. Probst, JNCI Journal of the National Cancer Institute	1996	148
Interleukin-2 in combination with interferon-α and 5-fluorouracil for metastatic renal cell cancer Jens Atzpodien, Hartmut Kirchner, Enrique Lopez Hänninen, European Journal of Cancer CytokineUrologyGenitourinary CancerMedicineImmunology	1993	145

Page 1